EURECA-m & CKD-MBD CME Meeting
September 13-15, 2018
Macedonia Palace Hotel
Thessaloniki, Greece

Thursday, September 13
16:30 Registrations
17:00-17:15 Welcome and Introduction  P. Sarafidis, A. Papagianni
17:15-18:00 Session 1
Introductory Lecture on History of Nephrology topic
18:00-20:00 Session 2
- Raymond Vanholder  Metabolomics approach to cardiovascular risk in CKD
- Jolanta Malyszko  Atrial Fibrillation in CKD: an undying, scarcely focused problem
- Aikaterini Papagianni  An update on the role of FGF-23 and Klotho axis in cardiovascular disease
- Fransesca Mallamaci  Sleeping disordered breathing in CKD: relevance for cardiovascular and renal outcomes

Friday, September 14
09:00-11:00 Session 3
- Mario Cozzolino  Vitamin D rehabilitated for vascular health
- Etienne Cavalier  Biomarkers from bone.....and beyond!
- Peter Stenvinkel  Inflammation at the crossroad of MBD and cardiovascular disease
- Ziad A. Massy  Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney Disease
11:00-11:30 Coffee-Break
11:30-13:30 Session 4
- Patrick Rossignol  Resistant hypertension in CKD: epidemiology and pathophysiology
- Costas Tsioufis  Update on pharmacologic and interventional treatment of resistant hypertension
- Andrzej Więcek  Renal denervation – a chance to slow the CKD progression?
- Pantelis Sarafidis  Ambulatory BP, pulse wave analysis and BP variability: potential value in dialysis
13:30-15:00 Lunch Break
15:00-17:00 Session 5
- Charles Ferro Myocardial fibrosis in CKD - from clinic to laboratory and back to the clinic
- Gunnar Heine Treatment of HF with reduced ejection fraction in CKD patients
- Patrick Mark Stroke and vascular cognitive decline in CKD- what are the targets for intervention?
- Apostolos Tsapas Cardiovascular and renal effects of SGLT-2: a unique opportunity for diabetic patients with CKD?

17:00-17:15 Coffee-Break

17:15-19:00 Session 6
- Jose Valdivielso Atherosclerosis in CKD: is it really different from the general population?
- Robert Ekart Obesity in patients with CKD: an unappreciated epidemic?
- Mehmet Kanbay An update about uric acid in CKD: What should we know and do?
- Michael Doumas Sexual dysfunction in CKD: a circulatory defect or more?

Saturday, September 15
09:00-11:00 Session 7
- Joao Frazão The Bone-Vessel axis
- Marc Vervloet Vascular phosphate toxicity revisited
- Mariano Rodriguez The role of dietary fat in vascular calcification
- Gerard London Parathyroid Hormone as a cardiovascular risk factor in CKD: a reassessment in 2018

11:00-11:15 Coffee-Break

11:15-13:15 Session 8
- Pablo Ureña-Torres Effects of antihypertensive treatment on the skeleton”?
- Alberto Ortiz Sex differences in CKD incidence and outcomes: beyond sex hormones?
- Marianne Verhaar Regenerative nephrology: a 2018 update
- Danilo Fliser RAAS blockade and hyperkalemia - a cause of concern or not?